Home › Research › Drug development
What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia?
Bradford B. Worrall, Rajiv R. Ratan. Neurology Genetics, 2026-09-25
Topic: Brain proteins, microglia and lab models
Mary Poppins famously asserted that "a spoonful of sugar helps the medicine go down," but this bon mot is likely wrong in almost every way.In fact, anecdotal and experimental data suggest health and longevity benefits to nutritional scarcity.The Western diet, with its heavy use of added sugars and high-fructose corn syrup in drinks and snacks, has contributed to the epidemics of type 2 diabetes (T2DM) and obesity, with adverse cardiometabolic effects and growing health consequences.1 Stroke remains a significant, growing public health burden in the United States. 2 The combined burden of Alzheimer disease and related dementias (ADRDs) is primarily driven by cardiometabolic morbidity.3 That spoonful of sugar causes a spike in blood glucose, disrupts homeostasis, and may have adverse consequences for the brain.The observations of Caro et al. 4 in this issue of Neurology ® and data from a host of sources are causing us to rethink how we can leverage glucose modulation for therapeutic benefit.5 Over nearly a century, we have come to understand the role that glucagon-like peptide-1 (GLP-1) and its receptor play in blood glucose regulation, ultimately leading to the development of GLP-1 receptor agonists (GLP-1RAs), first as treatment for diabetes and then for obesity.6 The first of these was derived from a GLP-1 analog in the venom of Gila monsters.In the 20+ years since their original release, evidence has emerged that these drugs may have cardiometabolic benefits beyond their original intent and independent of weight loss.A meta-analysis of 28 RCTs (74,148 patients) found a 27% reduction in ischemic stroke (RR 0.73; 95% CI 0.60-0.89) in treated patients with T2DM.7 The beneficial effects seem strongest for longacting GLP-1RAs, and the effect strengthens with longer periods of exposure.A target trial emulation in a population-based cohort study found that GLP-1RA use in T2DM was associated with a 33% lower risk of ADRDs compared with other glucose-lowering drugs.8 A metaanalysis of RCTs found that GLP-1RAs reduced odds of dementia/cognitive impairment by approximately 45%, a benefit not observed with other classes of drugs.9
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Worrall, B. B., & Ratan, R. R. (2026). What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia? Neurology Genetics. https://doi.org/10.1212/nxg.0000000000200450
Vancouver
Worrall BB, Ratan RR. What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia? Neurology Genetics. 2026. doi:10.1212/nxg.0000000000200450.
BibTeX
@article{worrall2026-1bda82c8,
author = {Worrall, Bradford B. and Ratan, Rajiv R.},
title = {{What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia?}},
journal = {Neurology Genetics},
year = {2026},
doi = {10.1212/nxg.0000000000200450},
url = {https://doi.org/10.1212/nxg.0000000000200450}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Mary Poppins famously asserted that "a spoonful of sugar helps the medicine go down," but this bon mot is likely wrong in almost every way.In fact, anecdotal and experimental data suggest health and longevity benefits to nutritional scarcity.The Western diet, with its heavy use of added sugars and h
Why it matters
This editorial discusses how diet, glucose regulation and GLP-1 receptor agonists relate to stroke and dementia risk. It presents commentary rather than new trial results on treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants74,148
- Effect sizeRR 0.73
- Evidence strengthHigh
How this study scored 61/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on impact for its field and year, so that was left out: it earned 57 of the 94 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology Genetics) |
| Journal's citation record | 0 / 4 | Neurology Genetics: journal h-index 53 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 74,148 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Rajiv R. Ratan: h-index 77 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Weill Cornell Medicine: institution h-index 1,163 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 57 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 57 of the 94 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.